Recent declines in biotechnology stock valuations suggest the industry has fallen into a trough, SVB Leerink said in a report on biopharmaceutical company capital formation, but the investment bank predicted that – based on past trends – valuations should emerge from the trough during the second quarter of 2022.
The 22 November report noted that biopharma valuations tend to follow a pattern of about four quarters of rising values...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?